Swissana Clinic AG has been acquired by Hirslanden AG
August 2014 — The private shareholders of Swissana Clinic AG have sold the company to Hirslanden AG for an undisclosed consideration.
Swissana Clinic AG was founded in 1995 and is one of the leading independent hospitals in central Switzerland. It is equipped with three operating rooms, offers 20 in-patient beds with first class comfort and a day hospital with 11 beds.
Hirslanden is the leading group of private hospitals in Switzerland and operates 16 facilities throughout the country. It is owned by Medi-Clinic International, a listed company from South Africa.
Our role in the transaction
Oaklins' team in Switzerland advised the sellers on the preparation of the divestment process and due diligence, the approach and negotiations with potential buyers, and assisted them until closing.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn more